ReviewProstate cancer and prostatic diseases2019
Approaches to urinary detection of prostate cancer.
Review in Prostate cancer and prostatic diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Exposing the Influence of Preceding Sexual Behavior in Younger Years toward Prostate Cancer Occurrence: Qualitative Mapping on Sexual Risk Factors.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis.Frontiers in oncology · 2022Pooled it
- Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Urine-based PSMA detection for noninvasive prostate cancer diagnosis: recent advances, translational challenges, and future perspectives.Frontiers in oncology · 2026Review
- Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO).Scientific reports · 2025Article
- Non-DRE Voided Urine Test to Diagnose Prostate Cancer: Updated Results.Diagnostics (Basel, Switzerland) · 2025Article
- Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.The Prostate · 2025Article
- Prostate cancer theragnostics biomarkers: An update.Investigative and clinical urology · 2024Review
- Recent Electrochemical Advancements for Liquid-Biopsy Nucleic Acid Detection for Point-of-Care Prostate Cancer Diagnostics and Prognostics.Biosensors · 2024Review
- Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.Scientific reports · 2024Article
- Article
- Review
- Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers' Performance.Current issues in molecular biology · 2023Review
- Differentially expressed glycoproteins in pre- and post-digital rectal examination urine samples for detecting aggressive prostate cancer.Proteomics · 2023Article
- Urinary DNA as a Tool for Germline and Somatic Mutation Detection in Castration-Resistant Prostate Cancer Patients.Biomedicines · 2023Article
- Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer.Smart medicine · 2023Review
- Detection of rare prostate cancer cells in human urine offers prospect of non-invasive diagnosis.Scientific reports · 2022Article
- Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research.American journal of human biology : the official journal of the Human Biology Council · 2022Review
- Segmentation of the prostate, its zones, anterior fibromuscular stroma, and urethra on the MRIs and multimodality image fusion using U-Net model.Quantitative imaging in medicine and surgery · 2022Article
- Urinary marker panels for aggressive prostate cancer detection.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProstate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, prognosis, disease monitoring, and prediction of treatment efficacy. In this review, we focus on important advances as well as future efforts needed to drive clinical innovation in this area of urine biomarker research for prostate cancer detection and prognostication.
methodsWe provide a review of current literature on urinary biomarkers for prostate cancer. We evaluate the strengths and limitations of a variety of approaches that vary in sampling strategies and targets measured; discuss reported urine tests for prostate cancer with respect to their technical, analytical, and clinical parameters; and provide our perspectives on critical considerations in approaches to developing a urine-based test for prostate cancer.
resultsThere has been an extensive history of exploring urine as a source of biomarkers for prostate cancer that has resulted in a variety of urine tests that are in current clinical use. Importantly, at least three tests have demonstrated high sensitivity (~90%) and negative predictive value (~95%) for clinically significant tumors; however, there has not been widespread adoption of these tests.
conclusionsConceptual and methodological advances in the field will help to drive the development of novel urinary tests that in turn may lead to a shift in the clinical paradigm for prostate cancer diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.